Progression risk of low-grade anal neoplasia.
Research type
Research Study
Full title
LOW-GRADE SQUAMOUS INTRAEPITHELIAL LESION PROGRESSION RISK IN HIV-POSITIVE MEN WHO HAVE SEX WITH MEN.
IRAS ID
241422
Contact name
Mayura Nathan
Contact email
Sponsor organisation
Homerton University Hospital
Duration of Study in the UK
0 years, 3 months, 31 days
Research summary
Anal cancer will be one of the fastest rising cancers concerning incidence and mortality in the next two decades in the UK. Cervical and anal carcinogenesis are thought to be similar processes, they are caused by the same virus (human papillomavirus, HPV), affects similar tissue (squamocolumnar epithelium) and have the same precancerous lesions, denominated squamous intraepithelial lesions or intraepithelial neoplasia. There are several high-risk groups for anal HPV infection, anal precancerous lesions and anal cancer identified, and include HIV-positive individuals, men who have sex with men (MSM), women with lower genital tract neoplasia and transplant recipients. Patients diagnosed with low-grade squamous intraepithelial lesions (LSIL) or low-grade anal intraepithelial neoplasia (AIN1) are normally not treated, but kept under surveillance, frequently every 6 months, due to the risk of progression to anal high-grade lesions (HSIL) and/ anal cancer.
Studies on cervical disease showed that 10%-15% of low-grade lesions (CIN1) progress to high-grade lesions (CIN2/CIN3) in a two-year period. Information on the progression rate of anal LSIL/AIN1 to anal high-grade lesions are lacking. This information is important to understand which patients are likely to progress and need more close follow-up, and those that are unlikely to progress and hence could be discharged from surveillance or have a longer time interval between follow-up appointments.REC name
North West - Greater Manchester South Research Ethics Committee
REC reference
18/NW/0059
Date of REC Opinion
8 Feb 2018
REC opinion
Further Information Favourable Opinion